Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OVAS's Cash to Debt is ranked higher than
96% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. OVAS: No Debt )
OVAS' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
OVAS's Interest Coverage is ranked higher than
63% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
OVAS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 70.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -74.86
OVAS's ROE (%) is ranked higher than
65% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. OVAS: -74.86 )
OVAS' s 10-Year ROE (%) Range
Min: -102.08   Max: -80.21
Current: -74.86

-102.08
-80.21
ROA (%) -67.06
OVAS's ROA (%) is ranked higher than
62% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. OVAS: -67.06 )
OVAS' s 10-Year ROA (%) Range
Min: -87.56   Max: -72.25
Current: -67.06

-87.56
-72.25
ROC (Joel Greenblatt) (%) -2291.03
OVAS's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. OVAS: -2291.03 )
OVAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3579.1   Max: -2257.26
Current: -2291.03

-3579.1
-2257.26
» OVAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OVAS Guru Trades in

OVAS Guru Trades in

OVAS Guru Trades in

Q4 2014

OVAS Guru Trades in Q4 2014

Jim Simons 47,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.20
OVAS's P/B is ranked lower than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. OVAS: 19.20 )
OVAS' s 10-Year P/B Range
Min: 0   Max: 23.6
Current: 19.2

0
23.6
EV-to-EBIT -25.16
OVAS's EV-to-EBIT is ranked higher than
59% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OVAS: -25.16 )
OVAS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -25.16

Current Ratio 6.08
OVAS's Current Ratio is ranked higher than
85% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. OVAS: 6.08 )
OVAS' s 10-Year Current Ratio Range
Min: 6.08   Max: 15.32
Current: 6.08

6.08
15.32
Quick Ratio 6.08
OVAS's Quick Ratio is ranked higher than
85% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. OVAS: 6.08 )
OVAS' s 10-Year Quick Ratio Range
Min: 6.08   Max: 15.32
Current: 6.08

6.08
15.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.90
OVAS's Price/Net Cash is ranked higher than
69% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. OVAS: 20.90 )
OVAS' s 10-Year Price/Net Cash Range
Min: 3.61   Max: 21.26
Current: 20.9

3.61
21.26
Price/Net Current Asset Value 20.90
OVAS's Price/Net Current Asset Value is ranked higher than
68% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. OVAS: 20.90 )
OVAS' s 10-Year Price/Net Current Asset Value Range
Min: 3.53   Max: 20.66
Current: 20.9

3.53
20.66
Price/Tangible Book 18.90
OVAS's Price/Tangible Book is ranked higher than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. OVAS: 18.90 )
OVAS' s 10-Year Price/Tangible Book Range
Min: 2.42   Max: 5.87
Current: 18.9

2.42
5.87
Earnings Yield (Greenblatt) -4.30
OVAS's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. OVAS: -4.30 )
OVAS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.2   Max: 0
Current: -4.3

-8.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
OvaScience, Inc. was established in 2011 & is based in Cambridge, Massachusetts. The Company is a life science company developing proprietary products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011.
» More Articles for OVAS

Headlines

Articles On GuruFocus.com
Analyst Remains Bullish While OvaScience Posts Losses in Q4 Report Mar 18 2015 
OvaScience’s Fertility Treatment Shows Promise Jan 20 2015 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 


More From Other Websites
Additional Clinical Reports of OvaScience AUGMENT Fertility Treatment Show Improved Pregnancy Rates... Mar 28 2015
Analyst Calls OvaScience Study 'Promising,' But Shares Sink Mar 27 2015
OvaScience Inc Corporate Call - AUGMENT KOL scheduled for 10:00 am ET today Mar 27 2015
1:05 pm OvaScience announces that presentations of its AUGMENTSM fertility treatment reported... Mar 26 2015
OvaScience AUGMENT Fertility Treatment Shows Improved Pregnancy Rates in Women with Prior Failed IVF... Mar 26 2015
OvaScience, Inc. (OVAS) in Focus: Stock Surges 12.2% - Tale of the Tape Mar 25 2015
OvaScience to Host Conference Call and Webcast Presentation with IVF Specialists to Review Early... Mar 25 2015
OvaScience shares soar as fertility findings due Mar 24 2015
OVASCIENCE, INC. Financials Mar 24 2015
[$$] OvaScience Born to Run: Why Shares Could Double Mar 20 2015
Analyst: OvaScience's Volatility Reflects Investor Confusion Mar 18 2015
AUGMENT Fertility Treatment to be Highlighted at Society for Reproductive Investigation (SRI) Annual... Mar 17 2015
OvaScience CEO Michelle Dipp Elected as Young Global Leader by World Economic Forum Mar 17 2015
OvaScience reports 4Q loss Mar 16 2015
OvaScience reports 4Q loss Mar 16 2015
OVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2015
OvaScience Reports Fourth Quarter and Year End 2014 Financial Results Mar 16 2015
OvaScience to Participate in Credit Suisse Global Healthcare Conference Feb 26 2015
OvaScience to Participate in Credit Suisse Global Healthcare Conference Feb 26 2015
OvaScience to Present at Leerink Global Healthcare Conference Feb 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK